T he progression from traditional wound dressings, such as saline-soaked gauze, to more advanced therapies, such as moist-wound healing, has been welcomed by most health care professionals. The promotion of a moist-wound healing environment is accepted as being beneficial to wound healing and improving patient outcomes and has been recommended for use in evidence-based guidelines. 1 More recent developments, such as the widespread use of silver and antimicrobial dressings to reduce the risk of infection and active dressings to accelerate the natural healing process, offer further potential benefits. 2 However, the uptake and adoption of innovative dressings is often restricted because of limitations on reimbursement and coverage.
It has been a struggle to attain prompt and adequate reimbursement for many modern dressings, for example, through the drug tariff that determines the reimbursement and availability of dressings in the primary and community sectors in England. Although adoption tends to be improved in secondary care settings, uptake can often be restricted through the adoption of dressing formularies that determine which dressings are made available in hospital settings. While there is a trend toward formularies' adopting a more systematic evaluation of the evidence available to support dressings prior to use, many still rely on a crude approach in which price (rather than clinical and cost-effectiveness) dictates availability.
The restrictions on market access and adoption usually arise because of the increasing demand for evidence on the value of new technologies. Increasingly, agencies with responsibility for health care funding are demanding evidence of the clinical and economic benefits of new technologies compared to existing treatments prior to covering their costs. In doing so, health care funding agencies are seeking to optimize the improvements in health care that can be provided by their scarce budgets. Delays can and do occur when there is insufficient clinical or economic evidence to support the proposed price of a new technology.
The level of clinical and economic evidence in wound care remains relatively poor. This fact has been recognized by many of the evidence-based reviews of wound dressings. The Cochrane Wounds Group's review of the use of silver dressings in treating diabetic foot ulcers 3 concluded that (1) there were no published studies that met the inclusion criteria of the review and (2) "that trials are needed to determine clinical and cost effectiveness and longterm outcomes." This is despite the widespread use of silver dressings in practice. Similarly, a second review from the Cochrane Wounds Group found no evidence of the impact of dressings on pain in patients with venous leg ulcers. 4 These criticisms could be targeted at most wound dressings; however, the use of compression bandaging for managing venous leg ulcers, which is supported by robust clinical 5 and economic evidence 6 as well as a significant amount of audit data, 7 is a notable exception. Indeed, compression bandaging is one of the few areas of wound care in which the Cochrane Wounds Group identified a significant body of clinical evidence. 8 The root cause of the criticisms raised by the Cochrane Wounds Group and similar bodies is the absence of high-quality randomized controlled trials (RCTs) in wound care and a reluctance to consider evidence other than that derived from RCTs. The exclusion of other sources of potentially useful data (eg, well-designed longitudinal, observational studies) means that such groups run the risk of making recommendations based on an incomplete evaluation of the evidence base. Since these reviews have a significant influence on agencies with responsibility for funding, there is a real potential that the reviews could restrict the adoption of beneficial technologies.
In considering the evidence on a new health care technology, most appraisal groups apply a hierarchy of evidence, which has traditionally been applied to pharmaceuticals. While RCTs are required for the regulatory approval of new medicines, this is not the case for medical devices. This, coupled with the cost of conducting well-designed RCTs and the relatively low potential return on investment, means that there is little incentive for the manufacturers of dressings to undertake such studies prior to launching new products. As a result of this, much of the evidence generated to support the clinical and cost-effectiveness of wound dressings is generated in postlaunch studies in routine practice. These studies often adopt observational study designs intended to reflect standard practice. While this inevitably increases the risk of bias influencing the study results, it does mean that the study findings are likely to be generalizable to a wider audience. However, these studies are often dismissed by bodies that have responsibility for determining the coverage or reimbursement of new technologies.
Criticisms about the quality and extent of clinical evidence available to support wound dressings can be equally applied to the economic evidence on wound dressings. Economic evaluation of health care interventions relies to a great extent on the availability of robust clinical evidence. While economic modeling can overcome this to some extent by extrapolating the available clinical evidence, it is not a panacea for missing data. This has resulted in examples of well-designed economic models in wound care that have been undermined by the reliance on clinical findings that are not statistically significant. 9 The dearth of high-quality clinical literature on wound care goes a long way to explaining the absence of robust economic evidence to support the reimbursement of these technologies.
These issues create a dichotomous position: health care professionals working in wound care want access to the most innovative dressings. Health care funding agencies want to see evidence on dressings before including them on reimbursement or formulary lists. However, as there is little incentive to undertake RCTs prior to launch, evidence will be generated only once the dressings are made available to health care professionals.
The resolution of this issue relies on the collaboration of wound dressing manufacturers, funding agencies, and health care professionals. For their part, manufacturers of dressings must be more willing to invest in reliable clinical and economic evidence to support the adoption and reimbursement of new technologies. All health care funding involves an opportunity cost; funding a new technology in wound care means restricting funds for a new treatment for diabetes, coronary artery disease, cancer, or some other indication. Therapies in each of these areas come under intense scrutiny to determine whether they represent an efficient use of health care resources. As such, dressings should not be treated any differently, and manufacturers must accept that evidence on new technologies will be required prior to market access.
For their part, health care policy makers and payers must accept that wound care is complicated. While dressings are often perceived as being fairly low tech compared to other health care technologies, undertaking clinical studies of dressings is complex. Unlike studies of medical interventions, it is often impossible to blind study participants and difficult to determine an appropriate comparator and control for differences in supportive care. These practical differences mean that the quality of evidence on wound dressings is likely to be inferior to other health care interventions, particularly pharmaceuticals. The requirements for the regulatory approval of wound dressings also mean that there is little incentive to undertake RCTs prior to launch. Policy makers should take this into account and consider the potential of other sources of data, such as postlaunch observational studies or registries. While such study designs are inevitably open to more bias than an RCT is, the findings may prove to be more generalizable to the population of patients with chronic wounds. Such studies may also allow the limited adoption of new technologies in a controlled environment to generate evidence on their effectiveness prior to making them more widely available.
Finally, health care professionals also need to take some responsibility for the state of the evidence base to support wound care. The lack of a consensus on appropriate comparators and outcome measures in studies of wound care must be addressed if the evidence base is to improve. Health care professionals involved in research also have a responsibility to ensure that their research methods are fit for purpose.
Ultimately, collaboration among all 3 parties should lead to improvements in the clinical and economic evidence base to support chronic wound dressings and ensure that patients have timely access to the most advanced technologies available.
